Q-omics provides the consensus-scored TMEM40 profile across patient tissues and cancer cell-line models. TMEM40 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM40 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TMEM40 protein abundance shows 16,298 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, and HNSC as cancer lineages where TMEM40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM40 survival associations across molecular data types. TMEM40 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM40 RNA expression–survival associations across cancer types. High TMEM40 expression shows unfavorable associations in KIRC, KIRP, MESO, BRCA and COAD, but favorable associations in UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM40 RNA expression.
This table summarizes TMEM40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM40 shows lower tumor expression in KIRC and higher tumor expression in LUSC, LIHC, THCA, COAD and BLCA. The KIRC box plot shows higher TMEM40 RNA expression in normal versus tumor tissue (log2 FC = −0.110, t-test p < 0.001).
This table shows molecular features associated with TMEM40 in patient tissues and cancer cell lines. In patient samples, TMEM40 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM40 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
